Empire of Pain

Patrick Radden Keefe's Empire of Pain offers a fascinating and detailed look at the life of the Sackler dynasty, which built unimaginable wealth through the pharmaceutical industry. At first glance, this family appears as a symbol of philanthropy and cultural progress - their name adorns galleries, universities and museums around the world. But beneath that glossy surface lies a dark tale of greed, manipulation and devastation wrought by their flagship opioid drug, OxyContin. Patrick Radden Keefe goes behind the scenes of the family empire to uncover not only the causes of one of the greatest health crises in modern history, but also how systemic failures allowed this tragedy to flourish. The book is not just a critique of the Sacklers, but also a broader examination of the business ethics, responsibilities, and moral compromises that accompany the path to success.

The first key idea focuses on the origins of the wealth of the Sackler dynasty, who have become a symbol of luxury and prestige, but whose success rests on controversial foundations. Known for their generous donations to museums, universities and hospitals, the family built their empire on the pharmaceutical industry, specifically on products that changed the way the world viewed pain management. The history of the Sackler dynasty dates back to the mid-20th century, when three brothers - Arthur, Mortimer and Raymond Sackler - launched their pharmaceutical business. Arthur, the eldest and most ambitious of the brothers, was a visionary who combined medicine, marketing and psychology. As early as the 1950s, he introduced revolutionary marketing strategies for pharmaceutical products, gaining significant influence. Arthur's work with Valium, which became one of the first "blockbuster" drugs, foreshadowed his ability to influence doctors and the public. In the 1990s, the Sacklers entered the opioid market when their company, Purdue Pharma, launched OxyContin. This drug, designed as a powerful cure for chronic pain, brought the family billions in profits. What made it unique was its release system, which was supposed to ensure slow absorption of the active ingredient, thereby preventing addiction. However, these claims later faced serious criticism when it became clear that the drug was highly addictive. The Sackler family carefully cultivated an image as philanthropists who sought to support the arts, science and medicine. Their name appeared on the facades of prestigious institutions such as the Metropolitan Museum of Art in New York and the University of Oxford. But there was a flip side to this strategy - to obscure the origins of their wealth, which was increasingly associated with the devastating opioid crisis. It is important to understand that the Sacklers' wealth did not arise from drug development alone, but from their ability to control the market through aggressive marketing and control of the narrative. They persuaded doctors of OxyContin's safety and incentivized them to prescribe it through various bonuses and perks. This model not only increased their profits, but also made opioids a common part of medical practice. This book chapter shows how a combination of innovative ideas, marketing genius, and ruthless strategy can create some of the world's greatest fortunes, yet leave a trail of suffering and addiction in its wake. The Sacklers have thus become emblematic not only of success but also of the moral dilemmas that accompany the pharmaceutical industry.

The second key idea focuses on the widespread opioid crisis that erupted as a result of the addictive potential of OxyContin, the flagship product of Purdue Pharma, which was owned by the Sackler family. This crisis, which affected the entire United States, exposed not only the devastating consequences of opioid abuse, but also systemic failures in the pharmaceutical and health care industries. OxyContin was launched in 1996 with the bold claim that it was a breakthrough chronic pain medication that had minimal risk of addiction. The marketing campaign, in which Purdue Pharma invested millions of dollars, targeted physicians, hospitals and the public. Pharmaceutical representatives visited physicians and convinced them that the drug represented a revolutionary solution for patients with long-term pain. However, this optimistic image quickly ran up against reality. OxyContin contained high doses of oxycodone, a heroin-like substance that was extremely addictive. Although the tablets were designed to release the active ingredient gradually, users found ways around this mechanism - by crushing or dissolving the tablets, they ensured an immediate, intense effect. The rapidly growing number of addiction cases and overdose deaths began to change public perception of OxyContin. States such as West Virginia, Ohio, and Kentucky, where the drug was prescribed en masse, faced devastating consequences-family breakups, economic hardship, and increasing numbers of deaths. From 1999 to 2019, the opioid crisis has claimed more than 500,000 lives in the United States alone. The crisis was exacerbated when patients, who were already being denied prescriptions for OxyContin by their doctors, began looking for alternatives on the black market. Heroin and synthetic fentanyl became cheaper and more readily available substitutes, which only exacerbated the scale of the problem. This situation raised questions about the ethics of the pharmaceutical industry, drug regulation, and liability for the harm caused by societal misuse. The opioid crisis has also shown how a combination of marketing pressure and lack of information can become a public health disaster. Many states and cities began filing lawsuits against Purdue Pharma, with the Sacklers facing increasing public and legal pressure. This chapter of the book shows that behind the Sackler family's success was not only their business, but also the devastation of millions of lives.

The third key idea addresses the marketing practices that Purdue Pharma and the Sackler family used to push OxyContin into the marketplace. This chapter reveals how aggressive and manipulative strategies were able to persuade not only physicians but also the public to consider this drug a safe solution for treating pain, while keeping the real risks in the background. Purdue Pharma ran one of the most intense marketing campaigns in pharmaceutical history in the 1990s. They invested hundreds of millions of dollars in convincing doctors that OxyContin was a "miracle drug." Their salespeople received special training that taught them how to maximize sales - not only by highlighting the drug's positive effects, but also by actively downplaying the risk of addiction. They presented statistics that claimed that only "less than 1% of patients" become addicted, which was based on incomplete and misleading data. A key marketing tool was the so-called 'model medical group'. The Sacklers invited physicians to upscale conferences and seminars at prestigious resorts, where they presented OxyContin as a safe and effective drug. These events were not just about education, but served to create loyalty between the doctors and Purdue Pharma. Physicians who prescribed the most drugs received financial rewards or were invited to other "prestigious" events. Purdue Pharma also created special programs to reach out to the general public. They ran stories on television and in print about patients whose quality of life was supposedly improved by OxyContin. These campaigns often showed people who were able to return to work or family life after years of pain - all thanks to a "safe and effective" drug. This emotional manipulation particularly worked on chronic pain patients who urged their doctors to prescribe the drug. Marketing also targeted the weak regulatory environment. The prescribing and monitoring mechanisms at the time were inadequate, allowing Purdue Pharma to circumvent more rigorous risk assessment. Advertising materials did not warn of addiction, and when the first cases of abuse emerged, the company labeled them "user error," not a problem with the drug itself. These marketing practices became a model for how to rapidly expand with a pharmaceutical product in the marketplace. At the same time, however, they showed how aggressive marketing strategies can ignore the broader societal implications in terms of public health. This chapter reveals that OxyContin's success was built not only on the development of the drug, but primarily on its ability to convince the world that its risks did not exist - until it was too late.

The fourth key idea focuses on the family dynamics of the Sacklers, which were integral to their entrepreneurial success but also a source of conflict and tension. This chapter reveals how power, ambition, and differing views on business affected not only their business decisions but also relationships within the family. The Sackler family consisted of three brothers - Arthur, Mortimer and Raymond - who founded their pharmaceutical empire. Arthur, the eldest brother, was both a visionary and a controversial figure. It was he who first understood that success in pharmaceuticals depended not only on the development of drugs, but also on their effective marketing. However, his innovative ideas did not always resonate with his younger brothers, causing tensions at times. After Arthur's death in 1987, Mortimer and Raymond took control of the family business. Their relationship was more pragmatic, but still marked by rivalry. While Arthur preferred creativity and risk-taking, Mortimer and Raymond placed more emphasis on profitability and conservative management. These differences in approach were reflected not only in their business strategies but also in the way they invested their wealth. As the generations passed, family relationships became more complicated. Children of founders who inherited wealth and influence often disagreed with the ways in which their parents ran the business. These differences resulted in disputes over control of the company and the future direction of the family business. Some family members wanted to continue the tradition of philanthropy, while others focused on protecting their wealth from growing public criticism. The Sackler family was known for its desire to maintain control of its public image. However, disputes between individual members occasionally leaked to the surface and revealed cracks in their "perfect" story. When the media and the public began to associate their name with the opioid crisis, these internal divisions deepened even further. Some family members refused to acknowledge any responsibility, while others sought ways to mitigate the effects of the scandal. This chapter highlights that although the Sacklers were able to present a united front externally, internally they were divided by power struggles and conflicts. Family dynamics show how personal ambitions and differing values could affect not only the running of an empire, but also the very perception of the family name. This view of their inner world provides an important context for understanding the decisions that contributed to their rise and fall.

The fifth key idea addresses the conflict between the Sacklers' philanthropy and the growing public condemnation of their business. For years the family had built an image as generous supporters of the arts, science, and education, but gradually the darker side of the sources of their wealth began to be revealed, and their reputation was profoundly affected. The Sacklers' philanthropic activities were impressive - their name graced prestigious institutions around the world. The Metropolitan Museum of Art in New York, the Royal Academy of Arts in London, and Harvard University accepted their million-dollar donations and named exhibition halls, galleries, and libraries after them. However, their philanthropy was often seen as a way of 'whitewashing' their reputations as the public increasingly began to question the ethics of their business. As the opioid crisis grew, these questions became more pressing. Protests by activists, as well as pressure from the media, have forced several institutions to reconsider their alliance with the Sackler family. Artists such as Nan Goldin, who had themselves experienced the devastating effects of opioids, began organizing public protests and campaigns that drew attention to the Sacklers' ties to Purdue Pharma. Banners with slogans like "Blood Money" appeared outside galleries that bore their name. The institutional response was varied. Some, like the Guggenheim Museum, publicly rejected further donations from the Sacklers and began removing their name from their spaces. Others were reluctant to sever the relationship, fearing a loss of funding. But this process revealed a deeper problem: the extent to which public institutions are willing to put ethical values ahead of financial gain. The Sacklers' philanthropy was also a way to redirect attention away from the legal challenges they faced. By supporting education or health projects, they sought to create an image of a family "doing good." However, as the number of victims of the opioid crisis grew, this narrative increasingly clashed with reality. This chapter reveals a paradox: on the one hand, the Sacklers were funding cultural and scientific advances; on the other, their wealth was coming from a system that was causing enormous human suffering. This conflict between image and reality is central to the public condemnation that inevitably changed their place in history.

The last key idea of the book focuses on the legal consequences the Sacklers faced as a result of their involvement in the opioid crisis. This chapter offers a glimpse into the family's endless lawsuits, financial settlements, and attempts to maintain their wealth and avoid direct liability. As the opioid addiction epidemic gained momentum, more and more states, cities, and individuals began filing lawsuits against both Purdue Pharma and the Sacklers personally. The allegations focused on the practices by which the company promoted OxyContin, including misleading claims about its safety and concealing the risks of addiction. These lawsuits alleged that the Sacklers knowingly profited from the addiction and suffering of millions of people. The lawsuits revealed secret internal documents that showed family members were directly involved in the company's strategic decisions. For example, emails between family members and Purdue Pharma executives showed that the Sacklers not only knew about the rising rate of OxyContin abuse, but also discussed ways to increase sales despite warnings about the risks. These findings reinforced public and legal criticism of the family. Purdue Pharma declared bankruptcy in 2019 as part of a deal that was supposed to resolve thousands of lawsuits. The bankruptcy agreement included the creation of a multibillion-dollar fund to compensate victims of the opioid crisis, with the Sacklers agreeing to contribute approximately $4.5 billion. However, the agreement also included a clause that protected the family from further individual lawsuits, sparking a wave of outrage from victims and activists. At the same time, the family was transferring their wealth into offshore funds and investment schemes, ensuring that their personal assets would remain intact. These actions sparked further accusations of moral recklessness and hypocrisy. Meanwhile, the Sacklers have continued to claim that they bear no personal responsibility for the crisis, further polarising public opinion. The Sacklers' legal battles represent one of the biggest corporate scandals in modern history. They have exposed how wealthy families and large corporations can use their influence to manipulate the law and evade justice. This chapter provides a picture of how the pursuit of protecting wealth and power can become more important than responsibility for devastating social consequences. The Sacklers thus remain a symbol not only of corporate greed but also of the gaps in the justice system.

Empire of Pain is a deep dive into the world of power, money, and destruction that reveals how the pharmaceutical industry's hinterland can be transformed into an epicenter of crisis. The Sacklers, who have sought to maintain a public image as generous benefactors, remain a controversial symbol of how philanthropy can be used to hide dark truths. The book highlights the inevitable conflict between profit and responsibility, opening up a broader debate about regulation, corporate ethics and personal accountability. It is the story not only of one family, but also of a society that has allowed such a tragedy to emerge and persist. Patrick Radden Keefe offers the reader not only the facts, but also the questions that remain relevant - who is really responsible for the suffering, and how can we ensure that similar crises do not happen again? Empire of Pain is a chilling reminder that the price of human pain may be high, but it should never be a commodity for sale. Do you have feedback for us? We'd love it if you let us know your opinion on our content! Just send an email to feedback@rewio.app with the title of this book in the subject line and share your impressions!